DK263390A - Flagellinrekombinantgener, undeinsyrekloner, mikroorganismer, proteiner og vacciner indeholdende dem samt fremgangsmaade til deres ekspression - Google Patents
Flagellinrekombinantgener, undeinsyrekloner, mikroorganismer, proteiner og vacciner indeholdende dem samt fremgangsmaade til deres ekspression Download PDFInfo
- Publication number
- DK263390A DK263390A DK263390A DK263390A DK263390A DK 263390 A DK263390 A DK 263390A DK 263390 A DK263390 A DK 263390A DK 263390 A DK263390 A DK 263390A DK 263390 A DK263390 A DK 263390A
- Authority
- DK
- Denmark
- Prior art keywords
- proteins
- flagellin
- recombinant
- epitope
- genes
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 7
- 108010040721 Flagellin Proteins 0.000 title abstract 5
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 244000005700 microbiome Species 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 abstract 4
- 108020001507 fusion proteins Proteins 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 102000009016 Cholera Toxin Human genes 0.000 abstract 1
- 108010049048 Cholera Toxin Proteins 0.000 abstract 1
- 101710121417 Envelope glycoprotein Proteins 0.000 abstract 1
- 101710085938 Matrix protein Proteins 0.000 abstract 1
- 101710127721 Membrane protein Proteins 0.000 abstract 1
- 241000702670 Rotavirus Species 0.000 abstract 1
- 241000194017 Streptococcus Species 0.000 abstract 1
- 102100021696 Syncytin-1 Human genes 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000003495 flagella Anatomy 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 201000004792 malaria Diseases 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19057088A | 1988-05-05 | 1988-05-05 | |
| PCT/US1989/001932 WO1989010967A1 (en) | 1988-05-05 | 1989-05-05 | Recombinant flagellin vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK263390D0 DK263390D0 (da) | 1990-11-02 |
| DK263390A true DK263390A (da) | 1991-01-04 |
Family
ID=22701885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK263390A DK263390A (da) | 1988-05-05 | 1990-11-02 | Flagellinrekombinantgener, undeinsyrekloner, mikroorganismer, proteiner og vacciner indeholdende dem samt fremgangsmaade til deres ekspression |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0419513B1 (da) |
| JP (1) | JP2793673B2 (da) |
| AT (1) | ATE121782T1 (da) |
| AU (1) | AU637049B2 (da) |
| CA (1) | CA1340817C (da) |
| DE (1) | DE68922394T2 (da) |
| DK (1) | DK263390A (da) |
| FI (1) | FI104638B (da) |
| NO (1) | NO302031B1 (da) |
| WO (1) | WO1989010967A1 (da) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698390A (en) * | 1987-11-18 | 1997-12-16 | Chiron Corporation | Hepatitis C immunoassays |
| US5712088A (en) * | 1987-11-18 | 1998-01-27 | Chiron Corporation | Methods for detecting Hepatitis C virus using polynucleotides specific for same |
| US6861212B1 (en) | 1987-11-18 | 2005-03-01 | Chiron Corporation | NANBV diagnostics and vaccines |
| US5714596A (en) * | 1987-11-18 | 1998-02-03 | Chiron Corporation | NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus |
| US6171782B1 (en) | 1987-11-18 | 2001-01-09 | Chiron Corporation | Antibody compositions to HCV and uses thereof |
| ES2070312T5 (es) * | 1988-12-19 | 2003-05-16 | American Cyanamid Co | Vacuna de proteina de membrana exterior meningococica de clase 1. |
| US7118757B1 (en) | 1988-12-19 | 2006-10-10 | Wyeth Holdings Corporation | Meningococcal class 1 outer-membrane protein vaccine |
| US6027729A (en) * | 1989-04-20 | 2000-02-22 | Chiron Corporation | NANBV Diagnostics and vaccines |
| DE69126786T2 (de) * | 1990-10-01 | 1998-01-08 | The Minister Of Agriculture Fisheries And Food In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain, London | Polynukleotidsequenz von salmonella |
| EP0551325B1 (en) * | 1990-10-01 | 2000-03-15 | The Minister Of Agriculture Fisheries And Food In Her Britannic Majesty's Gvt. Of The U. K. Of Great Britain And N. Ireland | Method of testing for salmonella |
| GB9101550D0 (en) * | 1991-01-24 | 1991-03-06 | Mastico Robert A | Antigen-presenting chimaeric protein |
| IL101639A0 (en) * | 1992-04-17 | 1992-12-30 | Yeda Res & Dev | Recombinant influenza vaccines |
| MXPA00012796A (es) * | 1999-12-28 | 2002-05-23 | Akzo Nobel Nv | Vacuna de salmonella. |
| JPWO2004055045A1 (ja) * | 2002-12-16 | 2006-04-20 | 株式会社シーエーエフラボラトリーズ | サルモネラ抗原処方物、それを使用した抗体検査キット及びサブユニットワクチン |
| JP2007535924A (ja) | 2004-05-07 | 2007-12-13 | − グスタフ ユングレン、ハンス | ワクチン用アジュバントとしてのフラジェリンの使用 |
| US7888064B2 (en) | 2004-12-02 | 2011-02-15 | Csir | Gram positive bacterial cells comprising a disrupted flagellin gene, flagellin-based fusion proteins and use in removal of metal ions from a liquid |
| AU2005325715B2 (en) | 2004-12-16 | 2011-10-06 | Wake Forest University Health Sciences | Use of flagellin in tumor immunotherapy |
| MY157941A (en) | 2005-01-19 | 2016-08-15 | Vaxinnate Corp | Compositions of pathogen-associated molecular patterns and methods of use |
| ES2534332T3 (es) | 2006-03-07 | 2015-04-21 | Vaxinnate Corporation | Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas |
| WO2009128950A2 (en) | 2008-04-18 | 2009-10-22 | Vaxinnate Corporation | Deletion mutants of flagellin and methods of use |
| US8932598B2 (en) | 2012-08-28 | 2015-01-13 | Vaxinnate Corporation | Fusion proteins and methods of use |
| CN102816246B (zh) * | 2012-09-04 | 2014-07-23 | 成都蓉生药业有限责任公司 | 一种人巨细胞病毒免疫原融合蛋白及其制备方法和用途 |
| JP2017530114A (ja) | 2014-09-26 | 2017-10-12 | バヴァリアン・ノルディック・アクティーゼルスカブ | フラジェリンをコードする組み換えｍｖａによる鼻腔内免疫のための方法と組成物 |
| EP3221464B1 (en) * | 2014-11-18 | 2022-02-23 | The Trustees of Columbia University in the City of New York | Detection of analytes using live cells |
| CN104402974B (zh) * | 2014-12-10 | 2017-11-14 | 重庆医科大学 | 一种具有粘膜免疫佐剂活性的多肽及其在制备粘膜免疫佐剂中的用途 |
| US10849938B2 (en) | 2017-09-13 | 2020-12-01 | ZBiotics Company | Gene expression system for probiotic microorganisms |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4735801A (en) * | 1982-09-07 | 1988-04-05 | Board Of Trustees Of Leland Stanford Jr. University | Novel non-reverting salmonella live vaccines |
| WO1987002385A1 (en) * | 1985-10-11 | 1987-04-23 | Genetics Institute, Inc. | Method for producing heterologous proteins |
| EP0237045B1 (en) * | 1986-03-11 | 1993-10-20 | Shionogi & Co., Ltd. | DNA encoding flagellin and vector having the same |
| CA1331355C (en) * | 1986-04-21 | 1994-08-09 | Bioenterprises Pty. Ltd | Immunopotentation |
-
1989
- 1989-05-05 CA CA000598847A patent/CA1340817C/en not_active Expired - Fee Related
- 1989-05-05 DE DE68922394T patent/DE68922394T2/de not_active Expired - Fee Related
- 1989-05-05 AU AU36979/89A patent/AU637049B2/en not_active Ceased
- 1989-05-05 WO PCT/US1989/001932 patent/WO1989010967A1/en active IP Right Grant
- 1989-05-05 EP EP89906507A patent/EP0419513B1/en not_active Expired - Lifetime
- 1989-05-05 JP JP1505981A patent/JP2793673B2/ja not_active Expired - Fee Related
- 1989-05-05 AT AT89906507T patent/ATE121782T1/de not_active IP Right Cessation
-
1990
- 1990-11-02 DK DK263390A patent/DK263390A/da not_active Application Discontinuation
- 1990-11-02 FI FI905441A patent/FI104638B/fi not_active IP Right Cessation
- 1990-11-05 NO NO904806A patent/NO302031B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0419513A1 (en) | 1991-04-03 |
| FI905441A0 (fi) | 1990-11-02 |
| DE68922394D1 (de) | 1995-06-01 |
| NO904806L (no) | 1991-01-03 |
| AU637049B2 (en) | 1993-05-20 |
| NO302031B1 (no) | 1998-01-12 |
| JP2793673B2 (ja) | 1998-09-03 |
| DE68922394T2 (de) | 1995-10-05 |
| CA1340817C (en) | 1999-11-09 |
| JPH04502402A (ja) | 1992-05-07 |
| NO904806D0 (no) | 1990-11-05 |
| WO1989010967A1 (en) | 1989-11-16 |
| FI104638B (fi) | 2000-03-15 |
| ATE121782T1 (de) | 1995-05-15 |
| AU3697989A (en) | 1989-11-29 |
| DK263390D0 (da) | 1990-11-02 |
| EP0419513B1 (en) | 1995-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK263390D0 (da) | Flagellinrekombinantgener, undeinsyrekloner, mikroorganismer, proteiner og vacciner indeholdende dem samt fremgangsmaade til deres ekspression | |
| EP2949340A1 (en) | Vaccine composition against Streptococcus suis infection | |
| DK153290D0 (da) | Polypeptid, vaccine indeholdende dette og ekspressionssystem indeholdende en dna-sekvens, der kan udtrykke polypeptidet | |
| DE60333035D1 (de) | Impfstoffe gegen infektionen mit dem humanen zytomegalivirus auf grundlage von codonoptimierten polynukleotiden | |
| WO2001091536A3 (en) | Genetic vaccine that mimics natural viral infection and induces long-lasting immunity to pathogens | |
| WO2005046621A3 (en) | Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines | |
| Liu et al. | DNA vaccines: mechanisms for generation of immune responses | |
| Bäckström et al. | Insertion of a HIV-1-neutralizing epitope in a surface-exposed internal region of the cholera toxin B-subunit | |
| JP2021505529A (ja) | ネコカリシウイルスワクチン | |
| Afchangi et al. | Immunization of mice by rotavirus NSP4-VP6 fusion protein elicited stronger responses compared to VP6 alone | |
| Rollier et al. | Early life humoral response of ducks to DNA immunization against hepadnavirus large envelope protein | |
| Muller et al. | Immunogenic measles antigens expressed in plants: role as an edible vaccine for adults | |
| Lee et al. | Tetanus toxin fragment C expressed in live Salmonella vaccines enhances antibody responses to its fusion partner Schistosoma haematobium glutathione S-transferase | |
| DE69739233D1 (de) | Ein durch labile bindung an einen träger gebundenes antigen enthaltender impstoff | |
| González et al. | Immunological characterization of a rotavirus-neutralizing epitope fused to the cholera toxin B subunit | |
| KR920006503A (ko) | 살모넬라 백신 균주의 표면에 면역원성 말라리아 항원을 발현할수 있는 재조합 발현 벡터 | |
| CY1105176T1 (el) | Χιμαιρικα νουκλεϊνικα οξεα και πολυπεπτιδια του ιου της λυσσας | |
| Arnon et al. | Peptide-based synthetic recombinant vaccines with anti-viral efficacy | |
| Perrin et al. | DNA-based immunization against Lyssaviruses | |
| JIANG et al. | Effects of the configuration of a multi-epitope chimeric malaria DNA vaccine on its antigenicity to mice | |
| Grosfeld et al. | Delineation of protective epitopes on the E2-envelope glycoprotein of Semliki Forest virus | |
| GB8431253D0 (en) | Biological preparations | |
| Ada | Desirable immunologic characteristics for the development of an ideal vaccine | |
| Jenkins et al. | Enhanced delivery systems for enteric antigen uptake in teleosts | |
| Fathizadeh et al. | OJVRTM |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AHS | Application shelved for other reasons than non-payment |